A Study of MGC026 in Participants With Advanced Solid Tumors

Summary

The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study. Participants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments if there are no severe side effects and as long as the cancer does not get worse.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Advanced Solid Tumor
• Advanced Cancer
• Metastatic Cancer
• Squamous Cell Carcinoma of Head and Neck
• Non Small Cell Lung Cancer
• Small-cell Lung Cancer
• Bladder Cancer
• Sarcoma
• Endometrial Cancer
• Melanoma
• Castration Resistant Prostatic Cancer
• Cervical Cancer
• Colorectal Cancer
• Gastric Cancer
• Gastro-esophageal Cancer
• Pancreas Cancer
• Clear Cell Renal Cell Carcinoma
• Hepatocellular Carcinoma
• Platinum-resistant Ovarian Cancer
• Breast Cancer
• Ovarian Cancer
• Esophageal Squamous Cell Cancer (SCC)

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

MacroGenics

Last updated on ClinicalTrials.gov

August 11, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites